The study 20050181 demonstrated significant improvements in progression-free survival ( PFS ) , objective response , and a nonsignificant trend toward increased overall survival ( OS ) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type ( WT ) KRAS metastatic colorectal cancer ( mCRC ) .